Management of Hyperkalemia Prevention in CKD Stage 3b

Current Risk Assessment

A patient with a GFR of 35 mL/min/1.73m² is at moderate risk for hyperkalemia, particularly with RAAS inhibitor use, and should be closely monitored 1, 2
Potassium levels of 4.4 mEq/L are below the threshold requiring intervention or medication adjustment, according to the European Heart Journal 3
The European Heart Journal recommends optimizing guideline-directed medical therapy rather than restricting it for patients with potassium levels in the safe range (4.5-5.0 mEq/L) 3

The European Heart Journal recommends up-titrating RAAS inhibitors to guideline-recommended target doses while monitoring potassium levels closely in patients with K+ levels of 4.5-5.0 mEq/L who are not on maximal guideline-recommended target doses 3
If potassium rises to 5.0-5.5 mEq/L during titration, consider initiating an approved potassium-lowering agent (patiromer or sodium zirconium cyclosilicate) to maintain RAAS inhibitor therapy rather than reducing the dose, as recommended by the European Heart Journal 3
Critical thresholds to remember: do not start RAAS inhibitors if K+ >5.0 mEq/L, reduce dose or stop if K+ >5.5 mEq/L, and stop immediately if K+ >6.0 mEq/L, according to the European Heart Journal 3

Non-potassium-sparing diuretics can help lower potassium levels in patients with chronic hyperkalemia, as stated in the European Heart Journal 3
If the patient develops hyperkalemia, reduce diuretic doses cautiously to decrease RAAS activation, provided no significant fluid retention exists, as recommended by the Journal of the American College of Cardiology and Circulation 4, 5

Eliminate potassium supplements entirely, as recommended by the European Heart Journal 3
Discontinue NSAIDs as they compromise renal function and increase hyperkalemia risk, according to the Journal of the American College of Cardiology and Circulation 4, 5
Use caution with mineralocorticoid receptor antagonists (MRAs) - not recommended if K+ >5.0 mEq/L, as stated in the European Heart Journal and Kidney International 3, 6

Implement dietary potassium restriction counseling through a renal dietitian, as emphasized in the KDIGO 2024 guidelines and Kidney International 1, 2
Limit foods rich in bioavailable potassium, particularly processed foods which have higher bioavailable potassium content, as recommended by Kidney International 1, 2

Establish a regular potassium monitoring schedule, checking potassium within 1-2 weeks after initiating or up-titrating RAAS inhibitors, and every 3-6 months once stable on medications, as recommended by the European Heart Journal and Kidney International 3, 1

Monitor for metabolic acidosis, which can worsen hyperkalemia risk, as stated in Kidney International 1, 2
Consider pharmacological treatment if serum bicarbonate <18 mmol/L, as recommended by Kidney International 1, 2

Be aware of local formulary restrictions for newer potassium binders (patiromer, sodium zirconium cyclosilicate), as stated in Kidney International 1, 2
Avoid chronic use of sodium polystyrene sulfonate (SPS) due to risk of bowel necrosis, as recommended by the European Heart Journal 3

Hyperkalemia risk increases substantially with diabetes mellitus, so screen for this comorbidity, as recommended by the Journal of the American College of Cardiology and Circulation 4, 5
If heart failure is present, balance the mortality benefit of RAAS inhibitors against hyperkalemia risk - the former typically outweighs the latter, as stated in the European Heart Journal and Journal of the American College of Cardiology 3, 4
Consider SGLT2 inhibitors if diabetic, as they may reduce hyperkalemia risk while providing cardiovascular and renal benefits, as recommended by Kidney International 6

The National Kidney Foundation recognizes that patients with chronic kidney disease (CKD), particularly those with eGFR <60 mL/min/1.73m², are at increased risk for hyperkalemia 7
In patients with heart failure and renal dysfunction, hyperkalemia is a common concern when using renin-angiotensin-aldosterone system (RAAS) inhibitors 8, 9

Potassium levels >5.5 mmol/L are considered elevated, with classifications of mild (5.5-6.4 mmol/L), moderate (6.5-8.0 mmol/L), and severe (>8.0 mmol/L) hyperkalemia 10
ECG changes associated with hyperkalemia include peaked T waves, PR interval prolongation, and QRS widening as potassium levels increase 10

ACE inhibitors and ARBs can increase potassium levels 8, 9
Loop and thiazide diuretics can decrease potassium levels 7
Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can cause hyperkalemia, especially in renal dysfunction 8

Regular monitoring of serum potassium is essential in patients with renal dysfunction 7
Careful medication management is required, with adjustment of RAAS inhibitors and diuretics based on potassium levels 9
Newer potassium binders (patiromer, sodium zirconium cyclosilicate) may help maintain normal potassium levels while continuing beneficial medications 7
In severe hyperkalemia (>6.5 mmol/L), urgent interventions may be needed, including calcium administration, insulin with glucose, beta-agonists, and/or dialysis 10

Discontinuing beneficial RAAS inhibitors prematurely due to mild, asymptomatic hyperkalemia 7
Overlooking non-prescription medications and supplements that may affect potassium levels 7